… -41. PROSPECTIVE SELECTION OF RECURRENT GLIOBLASTOMA PATIENTS FOR TAILORED THERAPIES. RESULTS OF AN INSTITUTIONAL EXPERIENCE
… of GBM treatment on the horizon are targeted therapy utilizing … In preliminary studies, we
prospectively selected recurrent … ), 14 bevacizumab plus erlotinib (bev+erl) and 4 bevacizumab …
prospectively selected recurrent … ), 14 bevacizumab plus erlotinib (bev+erl) and 4 bevacizumab …
[HTML][HTML] New directions in the therapy of glioblastoma
K Szklener, M Mazurek, M Wieteska, M Wacławska… - Cancers, 2022 - mdpi.com
… approved bevacizumab as a single agent for recurrent GBM … study, patients with progressive
or recurrent GBM received erlotinib (… ) showed the promising preliminary antitumor activity of …
or recurrent GBM received erlotinib (… ) showed the promising preliminary antitumor activity of …
[HTML][HTML] Molecular targeted therapies in glioblastoma multiforme: a systematic overview of global trends and findings
… recurrent GBM, with a survival of 24.8 months [109], while Pembrolizumab, with or without
bevacizumab, proved ineffective in therapy… , erlotinib (targeting EGFR), bevacizumab (targeting …
bevacizumab, proved ineffective in therapy… , erlotinib (targeting EGFR), bevacizumab (targeting …
[HTML][HTML] Small molecule inhibitors in adult high-grade glioma: from the past to the future
W Huang, Z Hao, F Mao, D Guo - Frontiers in Oncology, 2022 - frontiersin.org
… associated with small-molecule targeted therapies. Based on … , TMZ, radiotherapy, and
bevacizumab (Bev.). There are … A study in 2010 using erlotinib as monotherapy for recurrent GBM …
bevacizumab (Bev.). There are … A study in 2010 using erlotinib as monotherapy for recurrent GBM …
[HTML][HTML] Glioblastoma Therapy: Past, Present and Future
E Obrador, P Moreno-Murciano… - … Journal of Molecular …, 2024 - mdpi.com
… the SOC treatment and targeted therapies that have been … with TMZ/radiotherapy and/or
bevacizumab (BEV, recombinant … and erlotinib was tailored to the molecular profile of the patient’…
bevacizumab (BEV, recombinant … and erlotinib was tailored to the molecular profile of the patient’…
[HTML][HTML] Update on chemotherapeutic approaches and management of bevacizumab usage for glioblastoma
Y Funakoshi, N Hata, D Kuga, R Hatae, Y Sangatsuda… - Pharmaceuticals, 2020 - mdpi.com
… benefit of bevacizumab even for recurrent glioblastoma is controversial. … or do not qualify
for targeted therapies. … Preliminary analysis in the AVAglio study did not identify a predictive …
for targeted therapies. … Preliminary analysis in the AVAglio study did not identify a predictive …
Current therapeutic options for glioblastoma and future perspectives
E Aquilanti, PY Wen - Expert Opinion on Pharmacotherapy, 2022 - Taylor & Francis
… Lastly, we discuss therapeutics for recurrent glioblastomas … novel targeted therapies that
have shown promising preliminary … approval of bevacizumab for recurrent glioblastoma in 2009. …
have shown promising preliminary … approval of bevacizumab for recurrent glioblastoma in 2009. …
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
… future, molecular and cellular imaging approaches will more dynamically monitor the expression
of molecular … enabling more immediate adaptation of tumor-tailored, targeted therapies. …
of molecular … enabling more immediate adaptation of tumor-tailored, targeted therapies. …
The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential
C Anthony, N Mladkova-Suchy… - Expert opinion on …, 2019 - Taylor & Francis
… VEGF such as Bevacizumab (Bev) inhibit GBM growth in vivo [… therapeutic regimens, a study
of 10 recurrent GBM patients … Bev and erlotinib showed 100% PFS-6 in four patients whose …
of 10 recurrent GBM patients … Bev and erlotinib showed 100% PFS-6 in four patients whose …
Treatment of recurrent glioblastoma: state-of-the-art and future perspectives
V Di Nunno, E Franceschi, A Tosoni… - … of anticancer therapy, 2020 - Taylor & Francis
… OS but was aimed at a preliminary assessment of regorafenib … or bevacizumab in 369 patients
with recurrent glioblastoma. … erlotinib versus TMZ or carmustine in recurrent glioblastoma: …
with recurrent glioblastoma. … erlotinib versus TMZ or carmustine in recurrent glioblastoma: …